Greyson International Inc. Garners Investor Interest in a series of Financial Presentations Pre-empting an Investor Conference

Greyson International Inc. Garners Investor Interest in a series of Financial Presentations Pre-empting an Investor Conference

COCONUT CREEK, Fl. – Nov. 6, 2013- Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative patented trans-dermal and topical delivery emulsion targeting the multi-billion dollar anti-aging and OTC pharmaceutical industrieTia Headshots, unveiled details about the technology as well as business plans and market potential in a three-city series of financial presentations. The multimedia presentation delivered by Greyson Marketing Director, Tia Castle reveals the science behind Trilexon® technology and explains the vast applications in the pharmaceutical and anti-aging market.  A sixty-second preview clip of the presentation is also available which highlights how Trilexon® increases dermal permeation of anti-aging and/or topical pharmaceutical ingredients.

Tony Schor of Investor Awareness, director of the tri-city series remarked, “Now that the Company has a patent for Trilexon and is prepared to launch product, we felt it was the right timing to begin to tell the Greyson story to the financial community thru a series of financial presentations. We look forward to continuing our efforts in generating exposure and awareness on behalf of Greyson across the Country.”

“I felt this presentation explains the technology to both a lay and medical audience. But more importantly, I saw the light bulb go on when the audience of investors realized the enormous potential” said Tia Castle, Greyson International Marketing Director and Spokeswoman. She also added that an investor conference call will take place on Nov. 21, 2013 at 4:15 EST.  A reminder press release will be issued to announce details and the call in phone number.

 

Harvey Tauman, CEO of Greyson Inc. commented, “Our diligence in attaining a patent and test marketing Trilexon® has us on the verge of exploding into the market place as supported by the science you will see explained in this presentation. I am very proud to announce that our team will launch the new product line in the first quarter of 2014.” Greyson International recently hired consultant Joe Bovino, Esq., to head their pharmaceutical licensing division.  Joe has extensive relationships in the pharmaceutical industry having brokered many licensing deals for various companies.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer
Harvey@greysonintl.com

Greyson International Provides an Update on its Operations

Greyson International Provides an Update on its Operations

COCONUT CREEK, Fla.–(June 10, 2013)–Greyson International Inc. (OTC Pink: GYSN), developer of an innovative, patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced the sale of a portion of its interest in Blake Oil & Gas Limited (“Blake”), a privately owned, Guernsey registered oil and Gas Company with operations in the country of Georgia. The proceeds of approximately $1 million will be used to aggressively pursue retail distribution deals for its breakthrough Trilexon® powered products, as well as market Greyson Bio medical’s technology to potential licensees in the pharmaceutical industry.

Covered by U.S. Patent 8,268,335, Greyson International’s Trilexon® technology combines a cationic emulsifying agent, oil soluble liquid polymer and natural occurring lactate buffer system to dramatically improve the topical delivery of active ingredients in both the cosmetics and pharmaceutical industries.

“The sale of a portion of our interest in Blake provides us with the funding necessary to unlock the enormous potential in our breakthrough Trilexon® delivery technology across multiple end markets,” said Greyson International Inc. CEO Harvey Tauman. “We believe that Trilexon® will play a vital role in both the hypercompetitive cosmetics industry, where companies are always looking for a competitive edge, and the pharmaceutical industry where the larger players are facing so-called patent cliffs, and are looking for new ways to extend patent lives.”

Management will provide additional details about these programs as they are implemented over the coming months.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer
Harvey@greysonintl.com

 

Greyson International Inc. Hires TransMedia Group To Deliver Its Powerful Trilexon Story

BOCA RATON, Fla., Feb. 10, 2014 /PRNewswire/ — Greyson International Inc. (OTC Pink Sheets: GYSN) has retained TransMedia Group to introduce its patented transdermal delivery system Trilexon (www.greysonintl.com)focusing on both the beauty and pharma sectors in delivering anti-aging and prescription ingredients through the skin for maximum effectiveness.

TransMedia (www.transmediagroup.com) said it will publicize how Trilexon can resuscitate expiring pharmaceutical patents and save sales that otherwise would be lost over an ever widening, precipitous patent cliff.  TransMedia said it also will publicize a skin care line that Greyson plans to launch in the near future.  The industry stands to lose an estimated $90 billion from expired patents.

“When patents expire, companies face steep competition, causing revenues to drop off along with the value of their stock,” said Greyson Legal consultant Joe Bovino, “but Trilexon is a game changer as it will extend patent life of medications and other products.”

According to Greyson’s President and CEO Harvey Tauman, Trilexon enables active ingredients to be delivered topically instead of through the blood stream via swallowing a pill.

“Our publicity will show Trilexon enables ingredients to last longer and have greater impact as they’re contained in a unique emulsion.  Once water insoluble Trilexon is applied to skin, it acts as a breathable environmental dome, sealing in moisture and balancing pH,” said TransMedia CEO Tom Madden.

In his illustrious 40-year career in the cosmetics industry, Tauman was twice responsible for triple stock splits in companies he led and scoring a one-day record $2 million in sales on QVC, culminating in over $100 million in sales of his past cosmetic products, said Madden.

Greyson’s Brand Manager Tia Castle said that within Trilexon’s unique environment, actives such as medications, antioxidants and vitamins are able to release their full potential.

TransMedia said its publicity will show how Trilexon has the potential to reduce drug interaction and addictiveness and provide a power boost for skin and hair and long lasting SPF’s.

TransMedia will highlight how Greyson VP Mukeh Prasad assisted the late Charley Fox in developing Trilexon and how Fox believed Trilexon will help everyone in a way never thought possible.

Media contact: Iviani Figueroa 561-750-9800 x233; iviani@transmediagroup.com.

SOURCE TransMedia Group

Greyson International Inc. builds talent pool in preparation for resolving patent cliff panic

COCONUT CREEK, Fla. – July 2, 2013- Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that it recruited Tia Castle for the position of Brand Manager and Beauty Spokes Person for Greyson Skincare with Trilexon® technology.

Tia brings more than 15 years’ experience in both pharmaceutical sales and marketing with drug giant Johnson & Johnson (J&J). She is also an established on-air TV and film personality”, said Harvey Tauman, CEO of Greyson Inc.  Ms. Castle’s immediate role will be to manage the launch of Greyson Skincare on shopping networks, targeted for later this year, and appear as the on-air spokesperson. “I am excited to come on board full time, as I believe in Greyson’s ability to become a worldwide leader in skincare and pharmaceuticals. The potential to help companies stave off and recover from the ‘patent cliff’ is an enormous opportunity that needs immediate implementation,” said Tia Castle. “

The “patent cliff” is a big pharma company problem whereby brand names drugs that have delivered steady sales and profits are losing their patent protection. Greyson’s next news release will be detailing how their Trilexon® delivery system will give hope to the industry regarding the potential $90 billion loss.

Greyson International’s revolutionary patented Trilexon® delivery system allows the finest ingredients to be released topically over an extended period of time, while maintaining the skin’s natural intracellular barrier to promote natural moisture and lipid levels, providing a comfortable and durable experience that’s unlike anything else in the market.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer

Greyson International Inc. to Hold Investor Conference Call on Thursday, November 21, 2013

Greyson International Inc. to Hold Investor Conference Call on Thursday, November 21, 2013

Coconut Creek, Fla. – November 19, 2013 – Greyson International, Inc. (OTC Pink Sheets: GYSN), developer of an innovative-patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that it would be holding an investor conference call on Thursday, November 21, 2013, at 4:15 pm EDT. The conference call dial in number is 530-881-1300 and the Participant Access Code is 934487. The recorded version of the conference call will be available for playback after the call is concluded. Dial 530-881-1399 to listen.

“Our company has laid the foundation and set into motion the launch of Greyson Skincare, licensing deals and pharmaceutical joint ventures. I’m looking forward to giving details on these activities,” said Harvey Tauman, CEO of Greyson International Inc. “In addition, I’m looking forward to discussing our future plans on this call, as we bring our patented Trilexon trans-dermal delivery system to market and ultimately unlock significant value for our shareholders in 2014 and beyond.”

In preparation you may view the new videos on the Greyson website.

Welcome (Company & Technology Overview)

Detailed explanation of Trilexon® technology (second video)

Live Financial Investor Presentation Oct. 2013

 

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system that’s taking the multi-billion dollar cosmetics and OTC pharmaceuticals industries by storm. Based on this technology, the company’s patented Trilexon® foundation creates a fine surface that is insoluble in water, keeping it in place even after sweating or contact with water. Ingredients are released continuously over an extended period of time, ensuring that the skin receives treatment at a constant steady pace to give it a healthy and youthful look. In addition to cosmetic applications, Trilexon® has benefits in the medical field where it is important to deliver topical active ingredients. Trilexon® is a registered trademark of Greyson International. The company also holds an investment in Blake Oil and Gas Limited (“Blake”), a privately owned, Guernsey registered, Oil and Gas Company. For more information, visit our website; http://greysonintl.comand join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Harvey Tauman

Greyson International Inc.

Chief Executive Officer

(954) 482-0497

Harvey@greysonintl.com

Greyson International Inc. Provides Update on its Energy Assets

Coconut Creek, Fla. – February 28, 2013 – Greyson International Inc. (OTC Pink: GYSN), developer of an innovative, patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced an update on its passive investment in Blake Oil and Gas Limited (“Blake”), a privately owned, Guernsey registered oil and gas company with properties located in the country of Georgia.

“Greyson has been advised that the joint venture between Blake and the MND Group has been funded and new seismic data is being collected across all three properties. A drilling campaign is expected to commence later this year and continue through 2014.” said Greyson International Inc. CEO Harvey Tauman.

On March 12, 2012, Greyson acquired a private entity that resulted in a 3% passive ownership stake in Blake. On August 14, 2012, Blake entered into a joint venture agreement with MND Group whereby the latter received a 50% interest in Blake’s Georgian assets in exchange for assuming exploration and production costs. Under the terms of the agreement, the MND Group committed to over $100 million in capital expenditures to fund the development of the Ninotsminda, Manavi and Norio assets.

According to an independent report issued by Netherland, Sewell & Associates Inc. and Oilfield Production Consultants, these properties could have significant oil and gas reserves. More information about these assets can be found on Blake’s website, www.blakeoilandgas.com.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system that’s taking the multi-billion dollar cosmetics and OTC pharmaceuticals industries by storm. Based on this technology, the company’s patented Trilexon® foundation creates a fine surface that is insoluble in water, keeping it in place even after sweating or contact with water. Ingredients are released continuously over an extended period of time, ensuring that the skin receives treatment at a constant steady pace to give it a healthy and youthful look. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International. The company also holds an investment in Blake Oil and Gas Limited (“Blake”), a privately owned, Guernsey registered, Oil and Gas Company. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Harvey Tauman

Greyson International Inc.

Chief Executive Officer

(954) 482-0497

Harvey@greysonintl.com

Greyson International Inc. Releases Animated Motion Video Explaining their Patented Trilexon® Topical Delivery System

COCONUT CREEK, Fla. – Aug. 7, 2013- Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today made public on a YouTube video detailed information including an animated motion graphic explaining Trilexon® technology.  Video link: http://bit.ly/Trilexon

“I’m very proud to release this video. It’s an education regarding the applications and enormous potential of Trilexon®, it gives an intimate glimpse into what Greyson International has embarked upon and, it has enabled me to speak from my heart directly to the public” said Harvey Tauman, CEO of Greyson International Inc.

Greyson Int. is currently revamping their website to reflect initiatives stated in the video but will remain invisible on the website until all information is complete. A shareholder conference call is being announced shortly.

Greyson International’s revolutionary patented Trilexon® delivery system allows the finest ingredients to be released topically over an extended period of time, while maintaining the skin’s natural barrier to promote natural moisture and lipid levels, providing a comfortable and durable experience that’s unlike anything else in the market.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer
Harvey@greysonintl.com

Greyson International Provides Update on Prospective Biomedical Subsidiary

COCONUT CREEK, Fla. – April 10, 2013 — Greyson International Inc. (OTC Pink: GYSN), developer of an innovative, patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that Greyson is forming a subsidiary that will have a business plan which will target the multi-billion dollar pharmaceutical industry.

“Greyson’s management team has been diligently working to launch our new Greyson Biomedical subsidiary and commercialize Trilexon® Delivery System in potentially enormous medical end markets,” said Greyson International Inc. CEO Harvey Tauman. “After demonstrating efficacy in topical applications in OTC products, our goal is to license our patented technology to companies interested in improving efficacy of their existing products   or creating altogether new products.

Greyson International’s patented Trilexon® technology (U.S. Patent 8,268,335) combines a cationic emulsifying agent, oil soluble liquid polymer and naturally occurring lactate buffer system to dramatically improve the topical delivery of active ingredients. Unlike normal delivery agents, the patented formulation effectively delivers active ingredients to the skin at a more desirable pH level to enhance delivery/efficacy.

“We believe there is a lot of potential for Trilexon® Delivery System within the biomedical industry,” added CEO Harvey Tauman. “With more durable and stable delivery of active ingredients, we see potential in prescription products that promote healing, restore damaged cells, and relieve topical pain, as well as topical OTC products like pain relievers, eczema treatment, anti-itch creams, burn relief products, or sunscreens etc. Our team is working diligently to prove these claims and launching the new subsidiary in the near future in order to generate significant long-term value for our shareholders.”

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system that’s taking the multi-billion dollar cosmetics and OTC pharmaceuticals industries by storm. Based on this technology, the company’s patented Trilexon® foundation creates a fine surface that is insoluble in water, keeping it in place even after sweating or contact with water. Ingredients are released continuously over an extended period of time, ensuring that the skin receives treatment at a constant steady pace to give it a healthy and youthful look. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International. The company also holds an investment in Blake Oil and Gas Limited (“Blake”), a privately owned, Guernsey registered, Oil and Gas Company. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact

Greyson International Inc.
Harvey Tauman, 954-482-0497
Chief Executive Officer
Harvey@greysonintl.com

Greyson International Inc. receives industry expert validation regarding pharmaceutical patent cliff panic.

COCONUT CREEK, Fla. – July 22, 2013- Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that talks with patent law firm Lerner Greenberg Stemer LLP resulted in across the board agreement with Greyson’s plan to help save and stave the potential $90+ billion loss in the pharmaceutical market.

Large pharmaceutical companies are facing a so-called “patent cliff”, whereby brand names drugs, once having delivered steady sales and profits are losing, or have already lost, their patent protection.  Johnson and Johnson (NYSE:JNJ) has had three blockbuster drug patents expire in the last two years, Eli Lilly’s (NYSE:LLY) Cymbalta loses its patent at the end of 2013, and Pfizer (NYSE:PFE) recently attained a short extension on multibillion-dollar Celebrex which expires in Dec. 2015.

Lerner Greenberg Stemer LLP patent law firm for the world’s largest multinational corporations concur with Greyson’s plan to utilize their patented Trilexon® trans-dermal topical delivery system in several ways. “Leveraging our technology, large pharmaceutical companies can potentially reformulate their drugs to be delivered topically instead of orally, extend patent lives, and/or create new patents quickly under the Greyson umbrella” said Harvey Tauman, CEO of Greyson International Inc. “Greyson International, in addition to being debt free, has invested millions over a period of about 20 years culminating to the point whereby preparation is meeting opportunity.”

Currently Greyson International has anchored a large manufacturer, added two prominent physicians as consultants, and recruited top industry beauty consultants for Greyson Skincare® with Trilexon® technology.  Their new spokesperson and brand manager, Tia Castle is preparing to launch Greyson Skincare line on network shopping television toward the fourth quarter of 2013.  Greyson is open to adding new talent to the managerial team as it rapidly expands to meet market demands.  All inquiries may contact Harvey Tauman.

Greyson International’s revolutionary patented Trilexon® delivery system allows the finest ingredients to be released topically over an extended period of time, while maintaining the skin’s natural intracellular barrier to promote natural moisture and lipid levels, providing a comfortable and durable experience that’s unlike anything else in the market.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.

 

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contact:

Harvey Tauman

Greyson International Inc.

Chief Executive Officer

(954) 482-0497

Harvey@greysonintl.com

Greyson International, Inc. (OTC Pink Sheets: GYSN) Announces Agreement With The Shopping Channel To Offer Its Revolutionary New Skin Care Line For Sale In Canada

Greyson International, Inc. (OTC Pink Sheets: GYSN) Announces Agreement With The Shopping Channel To Offer Its Revolutionary New Skin Care Line For Sale In Canada

COCONUT CREEK, Fl., April 21, 2014 /PRNewswire/ — Greyson International, Inc. (OTC Pink Sheets: GYSN) announced today one of the leading interactive multi-channel retailers in North America, The Shopping Channel of Canada (tsc.ca), will offer for sale Greyson’s innovative new skin care line containing its patented transdermal delivery system Trilexon®  (www.greysonintl.com).

“This presents us with a marvelous sales opportunity for our company by offering consumers throughout Canada Greyson Skincare products containing our revolutionary delivery system,” said Greyson’s CEO Harvey Tauman.  The Trilexon Delivery System allows pharmaceutical and anti-aging ingredients to be released in the skin for extended periods for maximum effectiveness.

Greyson will offer for sale on The Shopping Channel its Perfect Balance Moisturizer, which minimizes fine lines and wrinkles, lifts skin and enforces the anti-oxidant barrier layer on skin by keeping the pH at 4.5-5. As well as its Clean Complex Foaming Cleanser and Pore Diminishing Toner, as great results begin with the foundation of a cleanser and toner. Trilexon’s cleanser and toner are engineered to clean without stripping, balances the pH to prepare the skin to readily accept.

About Greyson International, Inc.

Greyson’s primary focus is on its recently patented Trilexon® delivery system. In addition to cosmetic applications, Trilexon® may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon® is a registered trademark of Greyson International Inc. For more information, visit our web site; http://greysonintl.com and join the Greyson International’s Face book page http://www.facebook.com/GreysonInternationalInc.

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Contacts:

Greyson International Inc., Harvey Tauman, 954-482-0497,Chief Executive Officer, Harvey@greysonintl.com

Media contact: Abigail Blake 561-750-9800 x 2290; abby@transmediagroup.com.

SOURCE Greyson International, Inc.